| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
1 Department of Medical and Preventive Oncology, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genova, Italy
2 Division of Chemoprevention, European Institute of Oncology, 20141, Milano, Italy
3 Department of Health Sciences (DI.S.SAL.), University of Genova, 16132, Genova, Italy
(Requests for offprints should be addressed to A Decensi; Email: andrea.decensi{at}galliera.it)
Retinoids have been studied as chemopreventive agents in clinical trials due to their established role in regulating cell growth, differentiation and apoptosis in preclinical models. Experimental evidence suggests that retinoids affect gene expression both directly, by activating and/or repressing specific genes, and indirectly, by interfering with different signal transduction pathways. Induction of apoptosis is a unique feature of fenretinide, the most widely studied retinoid in clinical trials on breast cancer chemoprevention due to its selective accumulation in breast tissue and to its favourable toxicological profile. In a phase III breast cancer prevention trial, fenretinide showed a durable trend to a reduction of second breast malignancies in premenopausal women. This pattern was associated with a favourable modulation of circulating IGF-I and its main binding protein (IGF-binding protein-3, IGFBP-3), which have been associated with breast cancer risk in premenopausal women in different prospective studies. In a subsequent biomarker study on premenopausal women who had participated in the phase III trial, high IGF-I and low IGFBP-3 baseline levels were found to predict second breast cancer risk, although the magnitude of their changes during treatment did not fulfil the requirements for suitable surrogate end-point biomarkers. In postmenopausal women, fenretinide did not reduce second breast cancer incidence, nor did it induce significant modulation of the IGF system. Similarly, fenretinide was not found to affect risk biomarkers significantly in early postmenopausal women on hormone replacement therapy, who are at increased risk of developing breast cancer. Biomarker studies of fenretinide alone or in combination with different nuclear receptor ligands are being conducted. In particular, clinical trials of fenretinide and tamoxifen have proved to be feasible, and this combination appears to be safe and well tolerated in high-risk women, especially when low-dose tamoxifen is employed. Novel retinoid X receptor-selective retinoids, or rexinoids, have been shown to suppress the development of breast cancer in several animal models with minimal toxicity, and are being intensively studied either alone or in combination with selective oestrogen receptor modulators, both in vitro and in vivo. The rexinoid, bexarotene, has recently been approved for the treatment of patients with cutaneous T-cell lymphoma, and a biomarker trial with bexarotene in women with high breast cancer risk is currently underway.
This article has been cited by other articles:
|
|
 |
|
  F. Preitner, N. Mody, T. E. Graham, O. D. Peroni, and B. B. Kahn Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis Am J Physiol Endocrinol Metab, December 1, 2009; 297(6): E1420 - E1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ohashi, T. Kogai, H. Kagechika, and G. A. Brent Activation of the PI3 Kinase Pathway By Retinoic Acid Mediates Sodium/Iodide Symporter Induction and Iodide Transport in MCF-7 Breast Cancer Cells Cancer Res., April 15, 2009; 69(8): 3443 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Conzen Minireview: Nuclear Receptors and Breast Cancer Mol. Endocrinol., October 1, 2008; 22(10): 2215 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lu, K. A. Becker, M. J. Hagen, H. Yan, A. L. Roberts, L. A. Mathews, S. S. Schneider, H. T. Siegelmann, K. J. MacBeth, S. M. Tirrell, et al. Transcriptional Responses to Estrogen and Progesterone in Mammary Gland Identify Networks Regulating p53 Activity Endocrinology, October 1, 2008; 149(10): 4809 - 4820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Howe Rexinoids and Breast Cancer Prevention Clin. Cancer Res., October 15, 2007; 13(20): 5983 - 5987. [Full Text] [PDF]
|
|
|
|
 |
|
 M. N Pollak Insulin, insulin-like growth factors, insulin resistance, and neoplasia Am. J. Clinical Nutrition, September 1, 2007; 86(3): 820S - 821S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. McTernan and S. Kumar Retinol Binding Protein 4 and Pathogenesis of Diabetes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2430 - 2432. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes GADD153 (CHOP) and Bcl-2-Binding Component 3 (PUMA) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor Cancer Res., July 1, 2007; 67(13): 6270 - 6277. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
